TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Feb 25, 2022
|
|
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
Feb 24, 2022
|
|
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Feb 15, 2022
|
|
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
Jan 24, 2022
|
|
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Jan 05, 2022
|
|
TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million
Jan 04, 2022
|
|